4/1
09:46 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its price target lowered by analysts at Chardan Capital from $25.00 to $20.00. They now have a "buy" rating on the stock.
High
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its price target lowered by analysts at Chardan Capital from $25.00 to $20.00. They now have a "buy" rating on the stock.
4/1
08:00 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/31
07:32 am
sabs
SAB BIO Reports Full Year 2024 Operating and Financial Results
Medium
Report
SAB BIO Reports Full Year 2024 Operating and Financial Results
1/31
08:05 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
SAB BIO to Participate in Upcoming Investor Conferences [Yahoo! Finance]
1/31
07:00 am
sabs
SAB BIO to Participate in Upcoming Investor Conferences
Low
Report
SAB BIO to Participate in Upcoming Investor Conferences
1/29
11:28 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
Low
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.
1/29
08:18 am
sabs
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
1/28
07:00 am
sabs
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
High
Report
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
1/23
07:00 am
sabs
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
Medium
Report
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy